AdipoGen Life Sciences Gasdermin E (human) ELISA Kit

Gasdermin E is expressed in different tissues/cells, such as placenta, brain, heart, kidney, cochlea, intestines and IgE-primed mast cells. Specific cells express GSDME, and in such cells caspase-3 activation is switched from driving an apoptotic program to causing pyroptosis. Thus, certain cells are programmed to undergo pyroptosis instead of apoptosis.

GSDME-knockout mice were shown to be resistant to the toxicity of chemotherapy drugs such as cisplatin. GSDME-N terminal domain also permeabilises the mitochondrial membrane, releasing cytochrome C and activating the apoptosome. Recently it has been reported that granzyme B from killer cells activates caspase-independent pyroptosis in target cells by directly cleaving GSDME at the same site as caspase-3. Mutations in GSDME in humans are associated with development of heritable, non-syndromal deafness.

GSDME expression is suppressed in many cancers and reduced GSDME is associated with decreased breast cancer survival. GSDME gene expression has been shown to be associated with favourable prognosis following chemotherapy, and it could therefore be a potential predictive biomarker.

The Gasdermin E (human) ELISA Kit, from AdipoGen Life Sciences, detects the C-terminal domain of human Gasdermin E as well as the full-length protein. Upon cleavage of Gasdermin E and pore formation, the C-terminus fragment should be released in the extracellular space and found in serum/plasma.